An unfamiliar name goes after familiar targets
Soon after filing to float in Hong Kong, Baili takes HER2 and DLL3-targeting ADCs into the clinic.
ESMO 2024 preview – Astellas unveils its KRAS degrader
ASP3082 grabs some early attention among degraders set to feature at ESMO.
Novartis drops out of KRAS
While Roche, Lilly and Merck push on aggressively, Novartis throws in the towel.
The Revolution is here, and it’s... confusing
The group reaffirms pancreatic cancer promise with RMC-6236, but has it found the best dose?
Ideaya socks it to GSK
Two years after being snubbed by GSK, Ideaya shows the promise of MAT2A inhibition.
